Incorporating the Patient Perspective Into Your HIV Treatment Plan

Release Date: December 20, 2019
Expiration Date: December 20, 2020
Media: Internet - based

Activity Overview

The advent of antiretroviral therapy (ART), has granted the possibility of controlling the HIV epidemic. Adherence to ART helps maintain a low/undetectable viral load under control and prolong the time of progression to AIDS, resulting in near normal life expectancy. The availability of highly active antiretroviral therapy has provided tremendous breakthroughs such as suppression of virus replication and restoration of immunity in infected persons. HIV management requires life-long treatment, therefore some of the major obstacles physicians face with ART is the incidence of adverse effects of the treatment, pill burden and stigma, which persuade patients to discontinue the treatment. This activity is designed to update clinicians on the evolving landscape of treatment options in the management of HIV while incorporating the patient perspective into clinical decision making.

Benefits of Participating

• Raise awareness the importance of early diagnosis and treatment of HIV using efficacious antiretroviral therapy
• Apply the latest data from recently approved ART to develop optimal individualized treatment strategies for patients with HIV
• Learn the thought process of experts behind the management of specific patient cases across HIV and use these perspectives to confirm and update your clinical outcomes

Acknowledgement of Commercial Support

This activity is supported by an educational grant from ViiV Healthcare.

Target Audience

This activity is intended for HIV specialists, as well as physician assistants and nurse practitioners. Primary care physicians and pharmacists will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Select first-line ART regimens utilizing key clinical considerations
• Utilize clinical factors surrounding virologic failure in the selection of second-line ART in patients with HIV
• Outline the impact of common comorbid conditions on selection of ART regimens in patients diagnosed with HIV
• Identify barriers to HIV care, impact of HIV on health-related quality-of-life, and influence on patient adherence

Faculty, Staff, and Planners’ Disclosures

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine at Harbor-UCLA Medical Center
Professor of Medicine at David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA

Disclosures: Grant Research Support: Gilead Sciences, Inc.; Merck, ViiV; Consultant: Gilead Sciences, Inc.

Betty J. Dong, PharmD, FASHP, FAPHA, FCCP, AAHIVP
Professor of Clinical Pharmacy and Family and Community Medicine
Departments of Clinical Pharmacy and Family and Community Medicine,
Schools of Pharmacy and Medicine
University of California, San Francisco
San Francisco, CA

Disclosures: Other: American College of Clinical Pharmacy (ACCP); role as faculty panel chair in continuing education on HIV

Jason Tokumoto (Patient Interviewee)

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.